Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562344 | 1.00 | FPR2 (0.34) | FPR2KMT2AMEN1HSD11B1ELANE | |
| SCHEMBL7561306 | 0.94 | HSD11B1 (0.33) | KMT2AHSD11B1KDM4E | |
| SCHEMBL13055017 | 0.94 | HSD11B1 (0.33) | KMT2AHSD11B1KDM4E | |
| SCHEMBL7583861 | 0.89 | KMT2A (0.32) | KMT2AHSD11B1BDKRB1 | |
| SCHEMBL14105755 | 0.86 | MEN1 (0.35) | KMT2AMEN1HSD11B1ESR1OPRM1 | |
| SCHEMBL13054625 | 0.86 | ELANE (0.37) | ELANEKDM4ECYP2C9CYP3A4HTT | |
| SCHEMBL7576890 | 0.86 | ELANE (0.37) | ELANEKDM4ECYP2C9CYP3A4HTT | |
| SCHEMBL7565175 | 0.85 | AR (0.38) | KMT2AMEN1ELANEESR1KDM4E | |
| SCHEMBL13054495 | 0.85 | AR (0.38) | KMT2AMEN1ELANEESR1KDM4E | |
| SCHEMBL13054359 | 0.85 | ALDH1A1 (0.40) | KMT2ABDKRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | FPR2 3908/4885KMT2A 4458/4885MEN1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.